APA (7th ed.) Citation

Zakowiecki, D., Edinger, P., Papaioannou, M., Wagner, M., Hess, T., Paszkowska, J., . . . Haznar Garbacz, D. (2024). Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. Pharmaceutics, 16(11), 1485. https://doi.org/10.3390/pharmaceutics16111485

Chicago Style (17th ed.) Citation

Zakowiecki, Daniel, et al. "Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban." Pharmaceutics 16, no. 11 (2024): 1485. https://doi.org/10.3390/pharmaceutics16111485.

MLA (9th ed.) Citation

Zakowiecki, Daniel, et al. "Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban." Pharmaceutics, vol. 16, no. 11, 2024, p. 1485, https://doi.org/10.3390/pharmaceutics16111485.